Skip to Main Content

Paper Details

Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.
Cancer Discov
223
2014
AKT, BTK, BTK mutation, Bruton tyrosine kinase, C481S, C481S BTK, C481S BTK mutation, CDK4, MCL, MCL cells, PD 0332991, PI3K, PIK3IP1, cancer, cancers, human, ibrutinib, lymphoma, mantle cell lymphoma, palbociclib, patients, resistant, resistant MCL cells, resistant lymphoma, tyrosine
Author NameAffiliation
Kenneth EngWeill Cornell Medical College, New York. Tri-Institutional Training Program in Computational Biology and Medicine
Siraj M AliFoundation Medicine, Inc.
Betty Chang
Olivier ElementoWeill Cornell Medical College, New York. Institute for Computational Biomedicine
Olivier ElementoWeill Cornell Medical College, New York. Institute for Computational Biomedicine
Christopher E MasonWeill Cornell Medical College, New York. Institute for Computational Biomedicine
Christopher E MasonWeill Cornell Medical College, New York. Institute for Computational Biomedicine
  • 1 - 7

Datasets

Release 1.2